ストックスクリーナーアプリを入手
1.12
1.82%
0.02
アフターアワーズ：
1.12
前日終値:
$1.10
開ける：
$1.1
24時間の取引高:
9,926
Relative Volume:
0.42
時価総額：
$36.04M
収益：
-
当期純損益:
-
株価収益率:
-3.2175
EPS:
-0.3481
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-0.88%
1か月 パフォーマンス:
-3.45%
6か月 パフォーマンス:
-3.26%
1年 パフォーマンス:
-71.95%
1日の値動き範囲:
$1.10
$1.12
1週間の範囲:
$1.10
$1.15
52週間の値動き範囲:
$0.85
$4.40
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
名前
Akari Therapeutics Plc Adr
セクター
電話
(646) 350-0702
住所
22 BOSTON WHARF ROAD, BOSTON
AKTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
1.12 | 35.39M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-18 | 開始されました | Maxim Group | Buy |
| 2019-01-04 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | 開始されました | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | アップグレード | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | 繰り返されました | Chardan Capital Markets | Sell |
| 2016-07-11 | 開始されました | Chardan Capital Markets | Sell |
すべてを表示
Akari Therapeutics Plc Adr (AKTX) 最新ニュース
Akari Therapeutics advances cancer-fighting ADC technology with PH1 payload - Investing.com
Revolutionary Cancer Drug PH1 Targets KRAS, BRAF While Activating Immune System Against Tumors - Stock Titan
Akari Therapeutics CEO Shares Exclusive Insights on Next-Gen Cancer Drug Development Strategy - Stock Titan
INKT Stock Quote Price and Forecast - CNN
Akari Therapeutics shareholders approve equity plan increase and director elections - Investing.com
Akari Therapeutics Expands Global IP Portfolio: Key Patent Win for Cancer Drug Platform in India - Stock Titan
AKTX CEO buys 10,000 ADS at $1.20 in Form 4 insider filing - Stock Titan
Akari Therapeutics secures Indian patent for cancer drug payload - Investing.com India
Akari's Revolutionary Cancer Drug Technology Wins Key Patent in India's 2.08M Patient Market - Stock Titan
Akari Therapeutics CEO Reveals Latest Oncology ADC Developments at Major Webull Investor Event - Stock Titan
Akari Therapeutics Reports Q1 2025 Financial Results - TipRanks
Akari Therapeutics appoints new head of oncology business By Investing.com - Investing.com India
Akari Therapeutics appoints new head of oncology business - Investing.com
Akari Therapeutics' New CEO Reveals Future Roadmap: Key Insights from First Leadership Address - Stock Titan
Akari Therapeutics Advances ADC Development Amid Financial Challenges - TipRanks
Akari Therapeutics Transforms: Next-Gen Cancer Drug Shows Promise Amid 2024 Results - Stock Titan
Akari Therapeutics names new CEO to drive cancer drug innovation - Investing.com India
Akari Therapeutics names new CEO to drive cancer drug innovation By Investing.com - Investing.com South Africa
Ibotta Inc (IBTA) Shares Soar Above 1-Year High - The News Heater
Akari Therapeutics Appoints New CEO, Current CEO to Step Down By Investing.com - Investing.com South Africa
Akari Therapeutics Appoints New CEO, Current CEO to Step Down - Investing.com
Akari Therapeutics secures $7.6 million in private placement - Investing.com India
Acciones de Alibaba (BABA) caen tras medidas de Trump para frenar inversiones chinas en tecnología - Yahoo Finanzas
Citi reveló que Ecopetrol ha publicado la guía de sus resultados para el cuarto trimestre de 2024 - Yahoo Finanzas
Major ADC Developer Akari Opens Direct Channel to Investors Through Webull Platform - StockTitan
Akari Therapeutics appoints new CEO and board member - Investing.com
Akari Therapeutics Strengthens Leadership: Former CFO Returns After $50M Fundraising Success - StockTitan
Akari Therapeutics Regains Nasdaq Compliance, Secures Market Listing Status - StockTitan
Akari Therapeutics Completes Peak Bio Merger, Secures $53.2M in Financing Commitments - StockTitan
Akari Therapeutics Plc faces Nasdaq delisting over equity shortfall - Investing.com India
Riesgos y oportunidades sobre el futuro de la cotización de YPF - Yahoo Finanzas
¿Qué empresas del Ibex 35 también cotizan fuera de España? - Yahoo Finanzas
Bancolombia inicia programa para aumentar la liquidez de sus acciones - Yahoo Finanzas
Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology - StockTitan
Trending UK-Based Penny Stock Picks 2024 - timothysykes.com
Peak Bio (PKBO) Stock Price, News & Analysis - MarketBeat
Las 100 empresas latinoamericanas que se han lanzado a conquistar Wall Street - Yahoo Finanzas
Tras filtración de datos, las acciones de Globant se hundieron 10% - Yahoo Finanzas
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Yahoo Finance
AKTXAkari Therapeutics plc ADR (0.01 USD) Latest Stock News & Market Updates - StockTitan
Akari Therapeutics PLC Stock Price Today | NASDAQ: AKTX Live - Investing.com
Angion Biomedica (ANGN) Stock Price, News & Analysis - MarketBeat
ADVFN | Live Stock, Options & Crypto Market Data, Trading Tools & Community - ADVFN
Akari Therapeutics Plc Adr (AKTX) 財務データ
Akari Therapeutics Plc Adr (AKTX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):